Xianju Pharmaceutical (002332.SZ): Nicadipine hydrochloride injection passed the consistency evaluation

Zhitong Finance App News, Xianju Pharmaceutical (002332.SZ) issued an announcement. The company recently received the “Drug Supplement Application Approval Notice” (Notice No.: 2025B05803 and 2025B05804) for nicardipine hydrochloride injections approved and issued by the State Drug Administration. The company's nicardipine hydrochloride injections passed the consistent evaluation of the quality and efficacy of generic drugs. Nicardipine hydrochloride injection is a calcium ion antagonist drug, mainly used to rapidly lower blood pressure and treat acute hypertensive conditions, such as during surgery or emergency settings. It promotes blood flow by dilating blood vessels and protects important organs such as the heart, brain, and kidneys. It works quickly, but it needs to be used under medical supervision.